IP Library Granted Patent US 8,822,546
Granted Patent B2
US 8,822,546 · App. 12/325,514 · Granted Sep 2, 2014

Flowable pharmaceutical depot

Inventors: Michael Eric Benz (Ramsey, MN); Christopher M. Hobot (Tonka Bay, MN); Phillip Edward McDonald (Plymouth, MN); Lian Leon Luo (Shoreview, MN); John Kramer (Mt. Pleasant, MI)
Assignee: Medtronic, Inc.
A61K9/0024A61K47/34A61K31/4168A61K31/445
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,822,546
App. No.
12/325,514
Granted
Sep 2, 2014
Kind
B2
Abstract

Flowable pharmaceutical depots are described. The flowable pharmaceutical depot includes a polyester, such as a polylactic acid or a poly(trimethylene carbonate) endcapped with a primary alcohol and a pain relieving therapeutic agent, such as a post operative pain relieving therapeutic agent. Method of making and using the same are also described.

Claims (7)

1. A method comprising:

depolymerizing a polyester polymer with a primary alcohol to form an endcapped polyester polymer, wherein the primary alcohol comprises dodecanol and the polyester polymer comprises polylactic acid and the polylactic acid to dodecanol ratio is 2.68;

adding 4-dimethylaminopyridine to the polylactic acid and the dodecanol, where the polylactic acid polymer to 4-dimethylaminopyridine ratio is 1.64; and

combining the endcapped polyester polymer with a pain relieving therapeutic agent, forming a flowable pharmaceutical depot, wherein the pain relieving therapeutic agent comprises clonidine from 11 to about 20% by weight and where the flowable pharmaceutical depot does not cure or cross-link once administered in vivo.

2. A method according to claim 1 , wherein the flowable pharmaceutical depot has a viscosity in a range from 0.1 to 500 Pa·s.

3. A method according to claim 1 , wherein the pain relieving therapeutic agent further comprises bupivacaine.

4. A method according to claim 1 , further comprising blending a first polyester polymer endcapped with a primary alcohol having a first molecular weight in a range from 500 to 3000 g/mol with a second polyester polymer endcapped with a primary alcohol having a second molecular weight in a range from 500 to 3000 g/mol, wherein the first molecular weight is different than the second molecular weight.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2020
From: MEDTRONIC INC.
To: COMPANION SPINE, LLC
Reel/Frame 054787/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2008
From: BENZ, MICHAEL ERIC; HOBOT, CHRISTOPHER M.; MCDONALD, PHILLIP EDWARD; LUO, LIAN LEON; KRAMER, JOHN
To: MEDTRONIC, INC.
Reel/Frame 021947/0122 →
Continuity (1)
Related Publication 20100137369A1 · Jun 3, 2010